{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:04:03Z","timestamp":1782795843674,"version":"3.54.5"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background\/Objectives<\/jats:title><jats:p>Alopecia areata (<jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content>) is one of the most difficult skin diseases to manage well. In children, anthralin is commonly used for the treatment of <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content>. Available research consists of a limited number of uncontrolled trials that assessed the effectiveness of anthralin in promoting hair growth in patients with <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content>. The objective of this study was to validate the clinical effectiveness of short\u2010contact anthralin 1% ointment in children with AA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty children with chronic, severe, treatment\u2010refractory, extensive <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content> were treated with 1% anthralin ointment. One side of the scalp was treated with anthralin for 12 months and the other side was left untreated. Outcomes were evaluated according to the Severity of Alopecia Tool (SALT) score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean time to first response in terms of new hair growth was 3 months and the mean time to maximal response was 9 months. In the first 12\u2010month period, 10 patients (33.4%) achieved complete response to treatment and 11 patients (36.6%) had a partial response. Of the 11 patients with partial response at the end of the first year, 6 achieved a complete response before the end of the study. Total SALT scores for the entire scalp decreased from the end of the first year to the end of the 2\u2010year period. No serious adverse events were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anthralin 1% is an effective therapy for <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content> and should be continued at least 9 months. At 9 months of topical anthralin therapy, the patients with at least a 50% reduction in their pretreatment SALT scores should continue the same treatment for at least 1 year. Anthralin is safe in children with chronic, severe, treatment\u2010refractory, extensive <jats:styled-content style=\"fixed-case\">AA<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.13049","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T08:52:42Z","timestamp":1483433562000},"page":"128-132","source":"Crossref","is-referenced-by-count":29,"title":["Bilateral Half\u2010Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata"],"prefix":"10.1111","volume":"34","author":[{"given":"Mustafa","family":"\u00d6zdemir","sequence":"first","affiliation":[{"name":"Department of Dermatology School of Medicine Istanbul Medipol University Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Balevi","sequence":"additional","affiliation":[{"name":"Department of Dermatology School of Medicine Istanbul Medipol University Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92896-3"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0086-4"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01191.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70195-7"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01415.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.10.031"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12178.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12009"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000278241"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/jidsymp.2013.14"},{"key":"e_1_2_5_12_1","first-page":"101","article-title":"Management of alopecia areata: an update","volume":"5","author":"Majid I","year":"2012","journal-title":"Br J Med Pract"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1985.tb05863.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660350091020"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1979.04010100058026"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01476.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01781.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142869"},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2340\/0001555566179180","article-title":"A trial of 1% minoxidil used topically for severe alopecia areata","volume":"66","author":"Vestey JP","year":"1986","journal-title":"Acta Derm Venereol"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.13049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T21:30:12Z","timestamp":1696023012000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.13049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1111\/pde.13049"],"URL":"https:\/\/doi.org\/10.1111\/pde.13049","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,3]]}}}